Abstract Library

#2283 Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors

Introduction: Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Vandamme T

Authors: Vandamme T, Beyens M, Van Camp G, Boons G, Hofland L,

Keywords: pancreatic neuroendocrine tumors, PNET, genetics, tumor heterogeneity, hotspot mutations,

#1320 Are eIFs Ingredients for Neuroendocrine Tumorigenesis?

Introduction: Neuroendocrine tumors (NETs) develop in almost any organ, therefore they are a very heterogeneous group of tumors. One of the major activities in every cell is the translation of mRNA to the corresponding protein, which plays an important role in cancer development. Crucial for this translation process are eukaryotic initiation factors (eIFs), which are themselves regulated by the mammalian target of Rapamycin (mTOR)-pathway. Mutation or deregulated expression of eIFs influences cell growth and proliferation, contributing to carcinogenesis. The incidence of NETs has increased fivefold over the last three decades.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Haybaeck J

Authors: Gantenbein N, Smolle E, Thalhammer M, Kornprat P, Lackner C,

Keywords: NETs, mTOR, eukaryotic translation initiation,

#1307 Expression of m-TOR Pathway Components in Gastric Neuroendocrine Neoplasms: A Pilot Study

Introduction: The mammalian target of rapamycin (mTOR) signaling pathway plays a key role in the regulation of cell proliferation, protein synthesis and neuroendocrine tumor growth.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Delektorskaya V, Peregorodiev I, Bokhian V, Stilidi I,

Keywords: neuroendocrine, neoplasm, gastric, immunohistochemistry ,

#1244 Everolimus in Progressive Metastatic Pancreatic Neuroendocrine Tumors: Analyses of Median Progression Free Survival and Safety in the Real Life Setting

Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Del Prete M

Authors: Del Prete M, Malka L, Borget I, Berdelou A, Boige V,

Keywords: Pancreatic Neuroendocrine Tumor, Everolimus, Safety,

#1086 mTOR Down-Stream Signaling Pattern May Predict pNET Response to Everolimus

Introduction: NETs are rare neoplasms arising from neuroendocrine cells spread in the respiratory and gastro-entero-pancreatic epithelium. The mammalian target of rapamycin (mTOR) pathway plays a central role in the regulation of cell growth, metabolism, and apoptosis representing a novel molecular target. This pathway is constitutively activated in pancreatic NETs (pNETs) providing the basis for the development of specific mTOR inhibitors as new therapeutic tools.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Falletta S, Gagliano T, Gentilin E, Di Pasquale C, Benfini K,

Keywords: pNET, Everolimus, mTOR,